北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease
作者: Liu, Ye; Wei, Rui; Hong, Tian-Pei
关键词: Non-alcoholic fatty liver disease ; Glucagon-like peptide-1 ; Dipeptidyl peptidase-4 ; Insulin resistance ; Oxidative stress ; Lipid metabolism
刊名: WORLD JOURNAL OF GASTROENTEROLOGY
发表日期: 2014-07-21
DOI: 10.3748/wjg.v20.i27.9090
卷: 20, 期:27, 页:9090-9097
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Gastroenterology & Hepatology
研究领域[WOS]: Gastroenterology & Hepatology
关键词[WOS]: TYPE-2 DIABETES-MELLITUS ; INCRETIN-BASED THERAPIES ; DIPEPTIDYL-PEPTIDASE-IV ; HEPATIC STEATOSIS ; GLUCOSE-METABOLISM ; INSULIN-RESISTANCE ; MICE ; RECEPTOR ; STEATOHEPATITIS ; DIET
英文摘要:

Glucagon-like peptide-1 (GLP-1)-based therapies have demonstrated efficacy and safety in treating type 2 diabetes, which shares a similar pathophysiological mechanism with non-alcoholic fatty liver disease (NAFLD). Recent studies showed that glucose-induced GLP-1 secretion was decreased in patients with NAFLD and that the level of dipeptidyl peptidase-4, which inactivates intact GLP-1, was upregulated. Moreover, the expression of the GLP-1 receptor was downregulated in livers from patients with NAFLD, indicating an association of defective GLP-1 signalling with NAFLD. Notably, GLP-1-based therapies are reported to be effective in improving hepatic endpoints in patients with NAFLD, such as reducing hepatic fat content, hepatic steatosis and plasma transaminase levels, and preventing fibrosis. GLP-1-based therapies are beneficial for body weight control and glycaemic normalisation, which are important for the management of NAFLD. Moreover, clinical and preclinical studies showed that GLP-1-based agents might directly exert their actions on the liver through activation of functional GLP-1 receptors in hepatocytes. The possible mechanisms involve regulating gene expression that is associated with insulin resistance and lipid metabolism, and suppressing oxidative stress in the liver cells, thus preventing the development and progression of NAFLD. Based on these promising data, large-scale randomised controlled trials are warranted to assess the efficacy and safety of GLP-1-based therapies in treating NAFLD. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

语种: 英语
所属项目编号: 2012CB517502 ; 20120001120069
项目资助者: Chinese National 973 Program ; Research Fund for the Doctoral Program of Higher Education of China
WOS记录号: WOS:000339389600032
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54771
Appears in Collections:北京大学第三临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Hosp 3, Dept Endocrinol & Metab, Beijing 100191, Peoples R China

Recommended Citation:
Liu, Ye,Wei, Rui,Hong, Tian-Pei. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2014,20(27):9090-9097.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Liu, Ye]'s Articles
[Wei, Rui]'s Articles
[Hong, Tian-Pei]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Liu, Ye]‘s Articles
[Wei, Rui]‘s Articles
[Hong, Tian-Pei]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace